ÐÓ°ÉÔ­´´

OneChain Immunotherapeutics, based in Barcelona, specializes in developing CAR-T therapies for leukemia. This niche focus distinguishes them from traditional treatments like chemotherapy, radiation, and stem cell transplants, which often have lower survival rates, significant side effects, and longer treatment durations. Backed by Invivo Capital Partners, OneChain targets partnerships with larger healthcare providers and pharmaceutical companies. The growing demand for more effective and less harmful cancer treatments presents a strong growth opportunity for the company. Success will depend on clinical trial results, regulatory approvals, and the ability to scale production and establish key partnerships.